What U.S. hospitals can learn from a value-based strategy in the Netherlands

While healthcare costs continued to rise at other facilities, one Netherlands hospital was able to lower costs by 8 percent in a single year while improving quality. The credit goes to a value-based care strategy focusing on everything from closer coordination on cardiovascular patients to keeping more experienced physicians in the emergency department.

The 380-bed Bernhoven Hospital, located about 64 miles away from Amsterdam, does have to deal with a different regulatory structure. The Netherlands left single-payer healthcare a decade ago, for a heavily regulated private system where prices for services are set by the government, providers have to accept all insurance and being insured is compulsory.

Yet it faces the same problem as the U.S. healthcare system—unsustainable increases in costs. So Bernhoven’s strategy was to increase quality while reducing claims.

“We’re only going to do something if you’re really convinced that it has a lot of value. If not, we’ll stop it,” said PricewaterhouseCoopers consultant Sander Visser, who helped led the implementation of this strategy. “And in this way, we free up resources to invest back into the hospital to do further quality improvement.”

The hospital knew revenue would take a hit from this strategy. A key ingredient to the transition, Visser said, was entering into a multi-year agreement with insurers for a lump sum payment to help offset that drop in income. This allowed Bernhoven to focus on reducing utilization “no matter what it does to our reimbursements.”

The change in care delivery, however, was driven by the physicians. Doctors were given executive power in the hospital board and asked to come up with radical ideas for better care. More than 200 ideas were submitted, with the list then whittled down to strategies where the outcomes and costs could be estimated based on available research.

“When we say we put our physician in the lead, it’s easier said than done,” said Geert van den Enden, Bernhoven’s chief operating and chief financial officer. “You expect them to be think bigger, think wider, for the whole hospital.”

In one example, the hospital used quality data from a hospital where junior staff members went on strike, and discovered the more experienced physicians in the ER were less likely to admit patients. By introducing more veteran docs into the ER, admissions from the ER were reduced by 13 percent, along with drops in wait times, follow-up visits and length of stay. Part of the plan included having certain specialties represented in the department at all times.

“We wanted them to take shifts, senior cardiologists,” van den Enden said. “Because they’re way more experienced. They’ll see a patient and within half an hour, they’ll have a good plan, whereas the emergency doctor, a generalist normally, needs a little bit more time. I’m not saying they’re bad, but on different occasions, it’ll increase quality.”

The culture change appears to have paid off throughout the facility. Claims at Bernhoven decreased by 8 percent between 2014 and 2015, compared to a 2 percent increase in the rest of the Netherlands, and costs were down 16 percent through the first half of 2016.

Initiatives within other departments were also successful:

  • An awareness campaign for including patients in shared decision-making led to fewer surgeries. For example, after gall bladder patients discussed the pros and cons of their treatment options, “4 out of 6” decided against surgery for a “watchful waiting approach.”
  • The creation of an optometric consult center screened out more than 2,700 unnecessary visits to an eye MD (60 percent of all visits to the center). Each consultation without a referral saved $78 compared to seeing the MD.
  • Dermatologists saw patients at general practitioner offices, rather than at the hospital, with more than 80 percent of those visits not requiring a hospital referral.
  • 2,900 cardiovascular risk management (CVRM) patients were referred back to general practitioners rather than having follow-up consultations with the cardiologist at the hospital.

The individual initiatives weren’t necessarily new. What Visser felt was unique was Bernhoven implementing so many at once, with the unifying goal of a “relentless focus on eliminating overutilization.”

If other hospitals want to copy their methods, Visser said buy-in from physicians and the members of the board would be of the utmost importance. That would likely require getting the same financial commitments from the insurers as Bernhoven did, and the insurers will want something in return. In this case, it was the benefit of being able to applying what they’ve learned to other partnerships.

“Let’s bring these (lessons) to other hospitals, so on a national level, we can curb healthcare costs by a few (percentage points),” Visser said.

Both presenters warned there will be unavoidable consequences. By decreasing admissions and consultations in the first year of the project, Bernhoven lost 20,000 bed days, which means the hospital won’t need as many nurses.

After the presentation, Visser and van den Enden were asked by HealthExec whether American hospitals may struggle to copy Bernhoven’s care model due to regulatory differences between the two nations. Van den Enden said it may actually be easier in the U.S., as there are opportunities for vertical integration here which aren’t allowed in Netherlands.

“Your HMO systems, those are designed for this kind of work,” he said.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.